Last reviewed · How we verify
mupirocin 2% ointment
Mupirocin 2% ointment works by inhibiting bacterial protein synthesis, specifically targeting isoleucyl-tRNA synthetase.
Mupirocin 2% ointment works by inhibiting bacterial protein synthesis, specifically targeting isoleucyl-tRNA synthetase. Used for Treatment of impetigo, secondarily infected eczema, and minor cuts and scrapes.
At a glance
| Generic name | mupirocin 2% ointment |
|---|---|
| Also known as | Mupirocin |
| Sponsor | Philippine Dermatological Society |
| Drug class | bacterial protein synthesis inhibitor |
| Target | isoleucyl-tRNA synthetase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the bacteria from producing essential proteins, ultimately leading to cell death. Mupirocin is a potent inhibitor of bacterial growth, particularly effective against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes.
Approved indications
- Treatment of impetigo, secondarily infected eczema, and minor cuts and scrapes
Common side effects
- Skin burning sensation
- Skin irritation
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Bacterial Decolonization Within Dyads (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
- Decolonization to Reduce After-Surgery Events of Surgical Site Infection (PHASE4)
- Surgical Wound Infection Prevention Bundle in Patients Undergoing Coronary Bypass Graft Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |